Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining - PubMed (original) (raw)
Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining
S Takai et al. Int J Cancer. 1991.
Abstract
Plasminogen activator activity was investigated in extracts of 42 surgically removed gastric carcinomas. The mean levels of total plasminogen activator (total-PA) and urokinase-type plasminogen activator (u-PA) activities in the gastric carcinomas were significantly higher than those in the background normal tissues (p less than 0.001). On electrophoresis, gastric cancers were found to contain u-PA as the predominant PA, this being confirmed using zymography by direct inhibition with anti-urokinase antibody. Assessment of the relationship between PA activity and biological behavior of gastric cancer revealed total-PA and u-PA levels to be significantly higher in differentiated than in undifferentiated tumors (p less than 0.001), and in aneuploid than in diploid ones (p less than 0.01). Immunohistochemical staining showed that the proportion of u-PA-positive cancer cells in the carcinoma tissues also correlated with activity as measured by the azocaseinolytic method. These findings suggest that the study of PA contents in gastric cancer, combined with a nuclear DNA ploidy and immunohistochemical analysis, might be useful for understanding the biological characteristics of the tumor.
Similar articles
- Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E, Carroll VA, Jilch R, Mihaly J, Vesely M, Ulrich W, Pflüger H, Binder BR. Plas E, et al. Int J Cancer. 1998 Oct 29;78(3):320-5. doi: 10.1002/(SICI)1097-0215(19981029)78:3<320::AID-IJC11>3.0.CO;2-A. Int J Cancer. 1998. PMID: 9766566 - Relationship between plasminogen activators and stomach carcinoma stage.
Umehara Y, Kimura T, Yoshida M, Oba N, Harada Y. Umehara Y, et al. Acta Oncol. 1991;30(7):815-8. doi: 10.3109/02841869109091827. Acta Oncol. 1991. PMID: 1764272 - Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y, Suzumiya J, Marutsuka K, Sumiyoshi A, Hashida S, Ishikawa E. Hasui Y, et al. Cancer Res. 1989 Feb 15;49(4):1067-70. Cancer Res. 1989. PMID: 2492205 - Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
de Bruin PA, Verspaget HW, Griffioen G, Verheijen JH, Dooijewaard G, Lamers CB. de Bruin PA, et al. Br J Cancer. 1989 Sep;60(3):397-400. doi: 10.1038/bjc.1989.293. Br J Cancer. 1989. PMID: 2506920 Free PMC article. - Prognostic value of plasminogen activators and their inhibitors in colorectal cancer.
Verspaget HW, Sier CF, Ganesh S, Griffioen G, Lamers CB. Verspaget HW, et al. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1105-9. doi: 10.1016/0959-8049(95)00170-n. Eur J Cancer. 1995. PMID: 7577001 Review.
Cited by
- Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM. Allgayer H, et al. Clin Exp Metastasis. 1998 Jan;16(1):62-73. doi: 10.1023/a:1006564002679. Clin Exp Metastasis. 1998. PMID: 9502078 - Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Plebani M, Herszènyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F. Plebani M, et al. Clin Exp Metastasis. 1997 Jul;15(4):418-25. doi: 10.1023/a:1018454305889. Clin Exp Metastasis. 1997. PMID: 9219730 Clinical Trial. - Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB, Verspaget HW. Ganesh S, et al. Br J Cancer. 1997;75(12):1793-801. doi: 10.1038/bjc.1997.306. Br J Cancer. 1997. PMID: 9192984 Free PMC article. - Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler MA, Riesle E, Korc M, Büchler MW. Cantero D, et al. Br J Cancer. 1997;75(3):388-95. doi: 10.1038/bjc.1997.63. Br J Cancer. 1997. PMID: 9020484 Free PMC article. - Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N, Fujimura T, Nose H, Endo Y, Sasaki T. Ito H, et al. Virchows Arch. 1996 Feb;427(5):487-96. doi: 10.1007/BF00199509. Virchows Arch. 1996. PMID: 8624578
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous